Related Experiment Video
Updated: Jul 3, 2026

The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury
Published on: October 21, 2017
Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease
Kazuyoshi Takeda1, Yuko Kojima, Kenichi Ikejima
1Department of Immunology, Juntendo University School of Medicine, Hongo 2-1-1, Bunkyo-ku, Tokyo 113-8421, Japan. ktakeda@med.juntendo.ac.jp
Abstract:
Chronic cholestasis often results in premature death from liver failure with fibrosis; however, the molecular mechanisms contributing to biliary cirrhosis are not demonstrated. In this article, we show that the death signal mediated by TNF-related apoptosis-inducing ligand (TRAIL) receptor 2/death receptor 5 (DR5) may be a key regulator of cholestatic liver injury. Agonistic anti-DR5 monoclonal antibody treatment triggered cholangiocyte apoptosis, and subsequently induced cholangitis and cholestatic liver injury in a mouse strain-specific manner. TRAIL- or DR5-deficient mice were relatively resistant to common bile duct ligation-induced cholestasis, and common bile duct ligation augmented DR5 expression on cholangiocytes, sensitizing mice to DR5-mediated cholangitis. Notably, anti-DR5 monoclonal antibody-induced cholangitis exhibited the typical histological appearance, reminiscent of human primary sclerosing cholangitis. Human cholangiocytes constitutively expressed DR5, and TRAIL expression and apoptosis were significantly elevated in cholangiocytes of human primary sclerosing cholangitis and primary biliary cirrhosis patients. Thus, TRAIL/DR5-mediated apoptosis may substantially contribute to chronic cholestatic disease, particularly primary sclerosing cholangitis.
Insights
The TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor 2 (DR5) pathway drives cholestatic liver injury and biliary cirrhosis. Inhibiting this pathway may offer new treatments for primary sclerosing cholangitis.
Area of Science:
- Hepatology
- Immunology
- Cell Biology
Background:
- Chronic cholestasis leads to liver failure and fibrosis, but the underlying molecular mechanisms remain unclear.
- The TNF-related apoptosis-inducing ligand (TRAIL) pathway is implicated in cell death, but its role in cholestatic liver injury is not fully understood.
Purpose of the Study:
- To investigate the role of the TRAIL/TRAIL receptor 2 (DR5) pathway in the pathogenesis of cholestatic liver injury and biliary cirrhosis.
- To determine if targeting DR5 could be a therapeutic strategy for cholestatic liver diseases.
Main Methods:
- Utilized mouse models with targeted deficiencies in TRAIL or DR5.
- Administered agonistic anti-DR5 monoclonal antibodies to induce cholangiocyte apoptosis and liver injury.
- Examined DR5 expression and apoptosis in human cholangiocytes from patients with primary sclerosing cholangitis and primary biliary cirrhosis.
Main Results:
- Mice lacking TRAIL or DR5 showed resistance to common bile duct ligation-induced cholestasis.
- Anti-DR5 antibody treatment induced cholangitis and cholestatic liver injury in a strain-specific manner.
- Human cholangiocytes expressed DR5, with elevated TRAIL and apoptosis in patients with primary sclerosing cholangitis and primary biliary cirrhosis.
Conclusions:
- The TRAIL/DR5-mediated apoptosis pathway is a key regulator of cholestatic liver injury.
- This pathway contributes significantly to the development of chronic cholestatic diseases, including primary sclerosing cholangitis.
- Targeting DR5 presents a potential therapeutic avenue for managing these conditions.
Related Concept Videos
The Extrinsic Apoptotic Pathway
Cirrhosis II: Pathophysiology
Apoptosis
The Intrinsic Apoptotic Pathway
Cholesterol: Significance and Regulation
Considering cholesterol and...
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
